Attacking Neurodegenerative Diseases with Protein Degraders

The use of protein degraders is a promising area of emerging small molecule therapies. Rather than inhibit disease-causing proteins, degraders use a natural cellular process to break them down. Origami Therapeutics is using its proprietary drug discovery platform to...

Origami named part of the W22 Batch at Y Combinator

Oral drugs to halt neurodegeneration Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our...

Other events happening for Origami

28 Feb – 3 March, 2022 Presenting at 17th Annual Huntington’s Disease Therapeutics Conference https://web.cvent.com/event/a0991146-7ae2-4f10-bc6c-0bf856caac34/summary   28-30 March, 2022 Presenting at 10th Annual Neurodegenerative Drug Development Summit About...